It is known that Ibrutinib is the key for effective cancer treatment because it helps in the activation of the “switch” in cancer cells, thereby inducing apoptosis. An apoptosis response occurs when the cell’s protective walls are attacked by external agents or the growth factor drives the cell to reproduce inappropriately.
Apoptosis normally results in programmed cell death, but in case of cancer, it may lead to programmed cell suicide leading to tumor necrosis and cancerous transformation of surrounding tissues.
Since Ibrutinib is a powerful inhibitor of the tumor suppressor protein estrogen, it has the potential to shrink breast cancer tumors in the majority of patients with epithelioid cancers and to reduce the risk of prostate cancer in men.
The studies conducted so far have shown positive results in both cases. In addition, it has also shown good effects on pancreatic cancer and other types of cancer in animals.
In …read more >